TY - JOUR
T1 - Association of socioeconomic factors with the receipt of neoadjuvant therapy for patients with non–small cell lung cancer
AU - Elbahrawy, Mostafa M.
AU - Kamel, Mohamed K.
AU - Rodriguez-Quintero, J. Humberto
AU - Vimolratana, Marc
AU - Chudgar, Neel P.
AU - Stiles, Brendon M.
N1 - Publisher Copyright:
© 2023
PY - 2024/4
Y1 - 2024/4
N2 - Background: Neoadjuvant therapy (NT) will be increasingly used for patients with non–small cell lung cancer (NSCLC), particularly given the recent approval of neoadjuvant chemoimmunotherapy. Several barriers may prevent the uptake of NT and should be identified and addressed. We queried the National Cancer Database (NCDB) to determine predictors of the use of NT. Methods: Using the NCDB (2006-2019), we identified 80,707 patients who underwent surgery for clinical stage II and III NSCLC. Sociodemographic and clinical factors were reviewed, and univariable and multivariable analyses were performed to identify associations with the uptake of NT. In propensity score–matched groups, survival was determined using the Kaplan-Meier method. Results: Among 80,707 eligible patients, 17,262 (21.4%) received NT. Clinical stage and node positivity were associated with receipt of NT. On multivariable analysis, factors associated with lower rates of NT included black race (odds ratio [OR], 0.78; 95% confidence interval [CI], 0.67-0.90), Charlson Comorbidity Index ≥2 (OR, 0.75; 95% CI, 0.67-0.85), Medicaid/Medicare insurance (OR, 0.82; 95% CI, 0.75-0.90), lower income level (OR, 0.79; 95% CI, 0.71-0.87), and treatment at a community center (OR, 0.81; 95% CI, 0.67-0.96). In an exploratory analysis, those patients who received NT had longer 5-year overall survival compared with those who did not (48.3% vs 46.0%; P < .001). Conclusions: Rates of NT are relatively low for patients with clinical stage II/III NSCLC treated prior to recent chemoimmunotherapy trials. Socioeconomic barriers to the uptake of NT include race, insurance status, income, and area of residence. As NT becomes more widely offered, accessibility for vulnerable populations must be assured.
AB - Background: Neoadjuvant therapy (NT) will be increasingly used for patients with non–small cell lung cancer (NSCLC), particularly given the recent approval of neoadjuvant chemoimmunotherapy. Several barriers may prevent the uptake of NT and should be identified and addressed. We queried the National Cancer Database (NCDB) to determine predictors of the use of NT. Methods: Using the NCDB (2006-2019), we identified 80,707 patients who underwent surgery for clinical stage II and III NSCLC. Sociodemographic and clinical factors were reviewed, and univariable and multivariable analyses were performed to identify associations with the uptake of NT. In propensity score–matched groups, survival was determined using the Kaplan-Meier method. Results: Among 80,707 eligible patients, 17,262 (21.4%) received NT. Clinical stage and node positivity were associated with receipt of NT. On multivariable analysis, factors associated with lower rates of NT included black race (odds ratio [OR], 0.78; 95% confidence interval [CI], 0.67-0.90), Charlson Comorbidity Index ≥2 (OR, 0.75; 95% CI, 0.67-0.85), Medicaid/Medicare insurance (OR, 0.82; 95% CI, 0.75-0.90), lower income level (OR, 0.79; 95% CI, 0.71-0.87), and treatment at a community center (OR, 0.81; 95% CI, 0.67-0.96). In an exploratory analysis, those patients who received NT had longer 5-year overall survival compared with those who did not (48.3% vs 46.0%; P < .001). Conclusions: Rates of NT are relatively low for patients with clinical stage II/III NSCLC treated prior to recent chemoimmunotherapy trials. Socioeconomic barriers to the uptake of NT include race, insurance status, income, and area of residence. As NT becomes more widely offered, accessibility for vulnerable populations must be assured.
KW - National Cancer Database
KW - lung cancer
KW - neoadjuvant therapy
KW - non–small-cell lung cancer
KW - outcomes
UR - http://www.scopus.com/inward/record.url?scp=85174717463&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85174717463&partnerID=8YFLogxK
U2 - 10.1016/j.jtcvs.2023.09.033
DO - 10.1016/j.jtcvs.2023.09.033
M3 - Article
C2 - 37741315
AN - SCOPUS:85174717463
SN - 0022-5223
VL - 167
SP - 1458-1466.e4
JO - Journal of Thoracic and Cardiovascular Surgery
JF - Journal of Thoracic and Cardiovascular Surgery
IS - 4
ER -